Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy

World Journal of Urology

Volumn 33, Issue 8, 2015, Pages 1165-1171

  Mathieu, Romain ^a   Shariat, Shahrokh F ^b,d,e   Seitz, Christian ^b   Karakiewicz, Pierre I ^c   Fajkovic, Harun ^b   Sun, Maxine ^c   Lotan, Yair ^d   Scherr, Douglas S ^e   Tewari, Ashutosh ^e   Montorsi, Francesco ^f   Briganti, Alberto ^f   Rouprêt, Morgan ^g   Lucca, Ilaria ^b,k   Margulis, Vitaly ^d   Rink, Michael ^h   Kluth, Luis A ^h   Rieken, Malte ⁱ   Bachman, Alexander ⁱ   Xylinas, Evanguelos ^j   Robinson, Brian D ^e   Bensalah, Karim ^a   Margreiter, Markus ^b   more..

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j Paris Descartes University ^*  (France)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

Disease recurrence; Ki 67; Prognosis; Prostate cancer; Radical prostatectomy

Indexed keywords

KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER STAGING; CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; TUMOR INVASION; TUMOR RECURRENCE; VALIDATION STUDY;

ADULT; AGED; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84938952586     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1421-3     Document Type: Article

References (30)

1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124–137
2. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133(4):1710–1715
3. Kristiansen G (2012) Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 60(1):125–141
4. Shariat SF, Canto EI, Kattan MW, Slawin KM (2004) Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 6(2):58–72
5. Shariat SF, Karam JA, Margulis V, Karakiewicz PI (2008) New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 101(6):675–683
6. Wheeler TM, Lebovitz RM (1994) Fresh tissue harvest for research from prostatectomy specimens. Prostate 25(5):274–279
7. Gallee MP, Visser-de Jong E, ten Kate FJ, Schroeder FH, Van der Kwast TH (1989) Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J Urol 142(5):1342–1346
8. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P et al (1996) Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178(4):437–441
9. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW (1996) Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 156(3):1064–1068
10. Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL et al (1999) Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res 5(10):2820–2823
11. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, van der Kwast TH (2000) Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44 s in surgically treated patients with prostate cancer. J Urol 164(6):2156–2161
12. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA (2001) Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res 21(6A):4071–4076
13. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP et al (2002) Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 26(4):431–439
14. Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26(3):312–319
15. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Tenta R et al (2005) p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo 19(5):911–920
16. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T et al (2005) Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66(2):332–337
17. Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E et al (2005) Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 48(5):745–751
18. Shimizu Y, Segawa T, Inoue T, Shiraishi T, Yoshida T, Toda Y et al (2007) Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 100(3):685–690
19. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T (2008) EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 122(3):595–602
20. Goto T, Nguyen BP, Nakano M, Ehara H, Yamamoto N, Deguchi T (2008) Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urology 72(1):167–171
21. Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V et al (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 26(3):243–250
22. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M (2010) Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 28(2):145–151
23. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL et al (2012) An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 118(24):6063–6071
24. Kachroo N, Gnanapragasam VJ (2013) The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. J Cancer Res Clin Oncol 139(1):1–24
25. Zellweger T, Gunther S, Zlobec I, Savic S, Sauter G, Moch H et al (2009) Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 124(9):2116–2123
26. Shariat SF (2014) Incorporating biomarker research in a real-world setting: challenges of a prophecy. Urol Oncol 32(3):219–221
27. D’Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D et al (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95(2):281–286
28. Verze P, Scuzzarella S, Martina GR, Giummelli P, Cantoni F, Mirone V (2013) Long-term oncological and functional results of extraperitoneal laparoscopic radical prostatectomy: one surgical team’s experience on 1,600 consecutive cases. World J Urol 31(3):529–534
29. Bolton DM, Ta A, Bagnato M, Muller D, Lawrentschuk NL, Severi G et al (2014) Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer. World J Urol 32(2):431–435
30. Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52(6):1601–1609